Promising Phase II Results for New Drug to Treat Advanced Melanoma

Roche announced results from a Phase II clinical study of RG7204 (PLX4032), an inhibitor targeting the BRAF protein that is found in half of metastatic melanoma tumors.  The promising data was presented at the seventh International Melanoma Research Congress of the Society for Melanoma Research in Sydney, Australia.  Roche is currently working to open an expanded access program to offer more treatment options to patients with advanced stages of the disease.